S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
S&P 500   3,819.72
DOW   31,270.09
QQQ   309.16
Log in
NASDAQ:NBIX

Neurocrine Biosciences News Headlines

$95.01
-6.41 (-6.32 %)
(As of 03/3/2021 12:00 AM ET)
Add
Compare
Today's Range
$94.79
Now: $95.01
$101.18
50-Day Range
$101.42
MA: $112.20
$119.40
52-Week Range
$72.14
Now: $95.01
$136.26
Volume1.46 million shs
Average Volume926,549 shs
Market Capitalization$8.93 billion
P/E Ratio102.16
Dividend YieldN/A
Beta1.01

Headlines

Neurocrine Biosciences (NASDAQ NBIX) News Headlines Today

Source:
SourceHeadline
Neurocrine Biosciences (NASDAQ:NBIX) Upgraded to Hold at Zacks Investment ResearchNeurocrine Biosciences (NASDAQ:NBIX) Upgraded to Hold at Zacks Investment Research
marketbeat.com - February 11 at 12:45 AM
Neurocrine Biosciences Target of Unusually Large Options Trading (NASDAQ:NBIX)Neurocrine Biosciences Target of Unusually Large Options Trading (NASDAQ:NBIX)
americanbankingnews.com - March 3 at 1:59 PM
Neurocrine Biosciences (NASDAQ:NBIX)  Shares Down 7.3% Neurocrine Biosciences (NASDAQ:NBIX) Shares Down 7.3%
americanbankingnews.com - March 2 at 7:44 PM
Noteworthy Tuesday Option Activity: NBIX, LZB, ABRNoteworthy Tuesday Option Activity: NBIX, LZB, ABR
nasdaq.com - March 2 at 5:21 PM
Neurocrine Biosciences: Luvadaxistat Fails To Meet Primary Endpoint In Phase II INTERACT StudyNeurocrine Biosciences: Luvadaxistat Fails To Meet Primary Endpoint In Phase II INTERACT Study
nasdaq.com - March 2 at 12:20 PM
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)
finance.yahoo.com - March 2 at 12:20 PM
Neurocrine/Takedas Luvadaxistat Fails To Improve Schizophrenia Symptom SeverityNeurocrine/Takeda's Luvadaxistat Fails To Improve Schizophrenia Symptom Severity
finance.yahoo.com - March 2 at 12:20 PM
Neurocrine Biosciences to Present at the Cowen 41st Annual Health Care ConferenceNeurocrine Biosciences to Present at the Cowen 41st Annual Health Care Conference
finance.yahoo.com - February 23 at 8:00 PM
Reviewing Neurocrine Biosciences (NASDAQ:NBIX) and Vaxcyte (NASDAQ:PCVX)Reviewing Neurocrine Biosciences (NASDAQ:NBIX) and Vaxcyte (NASDAQ:PCVX)
americanbankingnews.com - February 18 at 2:20 AM
Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 1,700 Shares of StockInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 1,700 Shares of Stock
americanbankingnews.com - February 12 at 9:38 PM
Noteworthy Friday Option Activity: NBIX, WFC, RNGNoteworthy Friday Option Activity: NBIX, WFC, RNG
nasdaq.com - February 12 at 7:05 PM
Neurocrine Biosciences Upping Marketing Spend To Support Its PlatformNeurocrine Biosciences Upping Marketing Spend To Support Its Platform
seekingalpha.com - February 11 at 12:10 AM
Matt Abernethy Sells 2,910 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockMatt Abernethy Sells 2,910 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock
americanbankingnews.com - February 10 at 12:50 AM
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $98,739.75 in StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells $98,739.75 in Stock
americanbankingnews.com - February 9 at 11:14 PM
Eiry Roberts Sells 2,363 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) StockEiry Roberts Sells 2,363 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock
americanbankingnews.com - February 9 at 9:56 PM
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells $276,495.52 in StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells $276,495.52 in Stock
americanbankingnews.com - February 9 at 9:56 PM
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells $1,221,905.50 in StockNeurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells $1,221,905.50 in Stock
americanbankingnews.com - February 9 at 9:24 PM
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2020 Results - Earnings Call TranscriptNeurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 5 at 11:39 PM
NBIX Mar 2021 115.000 callNBIX Mar 2021 115.000 call
au.finance.yahoo.com - February 5 at 6:39 PM
NBIX Aug 2021 110.000 putNBIX Aug 2021 110.000 put
au.finance.yahoo.com - February 5 at 6:39 PM
Neurocrine Biosciences Inc (NBIX) Q4 2020 Earnings Call TranscriptNeurocrine Biosciences Inc (NBIX) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 5 at 1:07 AM
Neurocrine Biosciences Inc Q4 adjusted earnings Beat EstimatesNeurocrine Biosciences Inc Q4 adjusted earnings Beat Estimates
nasdaq.com - February 4 at 8:07 PM
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial ResultsNeurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results
finance.yahoo.com - February 4 at 8:07 PM
Recap: Neurocrine Biosciences Q4 EarningsRecap: Neurocrine Biosciences Q4 Earnings
finance.yahoo.com - February 4 at 8:07 PM
Neurocrine Biosciences (NBIX) Q4 Earnings Top EstimatesNeurocrine Biosciences (NBIX) Q4 Earnings Top Estimates
finance.yahoo.com - February 4 at 8:07 PM
NBIX Makes Notable Cross Below Critical Moving AverageNBIX Makes Notable Cross Below Critical Moving Average
nasdaq.com - February 1 at 3:44 PM
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial ResultsNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2020 Financial Results
finance.yahoo.com - January 20 at 8:51 PM
Neurocrine, Ionis, Vertex: Underperforming Healthcare Stocks Poised To RecoverNeurocrine, Ionis, Vertex: Underperforming Healthcare Stocks Poised To Recover
nasdaq.com - January 20 at 4:58 AM
Voyager Therapeutics: Complicated Story In Gene Therapy DevelopmentVoyager Therapeutics: Complicated Story In Gene Therapy Development
seekingalpha.com - January 19 at 6:56 PM
Neurocrine Biosciences Shares Rise Despite Disappointing Q4 Earnings; Target Price $121Neurocrine Biosciences Shares Rise Despite Disappointing Q4 Earnings; Target Price $121
finance.yahoo.com - January 8 at 7:27 PM
Bullish Two Hundred Day Moving Average Cross - NBIXBullish Two Hundred Day Moving Average Cross - NBIX
nasdaq.com - January 8 at 2:26 PM
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program MilestonesNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones
finance.yahoo.com - January 8 at 9:25 AM
Neurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare ConferenceNeurocrine Biosciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 7:56 PM
Voyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy ProgramVoyager Therapeutics Provides Update on NBIb-1817 (VY-AADC) Gene Therapy Program
finance.yahoo.com - December 22 at 6:01 PM
Should You Be Adding Neurocrine Biosciences (NASDAQ:NBIX) To Your Watchlist Today?Should You Be Adding Neurocrine Biosciences (NASDAQ:NBIX) To Your Watchlist Today?
finance.yahoo.com - December 21 at 2:39 PM
Is NBIX A Good Stock To Buy Now?Is NBIX A Good Stock To Buy Now?
finance.yahoo.com - December 21 at 2:39 PM
5 Top Biotech Stocks to Buy for 2021 With Massive Upside Potential5 Top Biotech Stocks to Buy for 2021 With Massive Upside Potential
msn.com - December 21 at 9:39 AM
Noteworthy Friday Option Activity: RARE, NBIX, KRANoteworthy Friday Option Activity: RARE, NBIX, KRA
nasdaq.com - December 18 at 6:41 PM
Neurocrine Stock Looks Attractive In the Wake Of A 30% CorrectionNeurocrine Stock Looks Attractive In the Wake Of A 30% Correction
forbes.com - December 16 at 1:48 PM
Is Neurocrine Biosciences (NBIX) a Smart Long-term Buy?Is Neurocrine Biosciences (NBIX) a Smart Long-term Buy?
finance.yahoo.com - December 11 at 9:26 AM
First Week of January 2021 Options Trading For Neurocrine Biosciences (NBIX)First Week of January 2021 Options Trading For Neurocrine Biosciences (NBIX)
nasdaq.com - November 20 at 2:59 PM
Neurocrine Biosciences Announces Repurchase of Convertible NotesNeurocrine Biosciences Announces Repurchase of Convertible Notes
finance.yahoo.com - November 19 at 8:28 AM
Neurocrine Biosciences Hit By Multiple SetbacksNeurocrine Biosciences Hit By Multiple Setbacks
seekingalpha.com - November 17 at 6:15 AM
Results: Neurocrine Biosciences, Inc. Delivered A Surprise Loss And Now Analysts Have New ForecastsResults: Neurocrine Biosciences, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
finance.yahoo.com - November 13 at 1:05 PM
Neurocrine Biosciences Inc (NBIX) Q3 2020 Earnings Call TranscriptNeurocrine Biosciences Inc (NBIX) Q3 2020 Earnings Call Transcript
finance.yahoo.com - November 10 at 8:42 PM
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call TranscriptNeurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q3 2020 Results - Earnings Call Transcript
seekingalpha.com - November 10 at 5:38 AM
Recap: Neurocrine Biosciences Q3 EarningsRecap: Neurocrine Biosciences Q3 Earnings
benzinga.com - November 9 at 6:14 PM
Neurocrine Biosciences EPS misses by $0.28, misses on revenue, FY outlookNeurocrine Biosciences EPS misses by $0.28, misses on revenue, FY outlook
seekingalpha.com - November 9 at 6:14 PM
Neurocrine Biosciences, Inc. to Host Earnings CallNeurocrine Biosciences, Inc. to Host Earnings Call
finance.yahoo.com - November 9 at 6:14 PM
Neurocrine Biosciences Reports Third Quarter 2020 Financial ResultsNeurocrine Biosciences Reports Third Quarter 2020 Financial Results
finance.yahoo.com - November 9 at 6:14 PM
Neurocrine Biosciences (NBIX) Reports Q3 Loss, Lags Revenue EstimatesNeurocrine Biosciences (NBIX) Reports Q3 Loss, Lags Revenue Estimates
finance.yahoo.com - November 9 at 6:14 PM
This page was last updated on 3/4/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.